NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS Acuity Brands ( AYI) upgraded at Keybanc to Buy. $50 price target. Company is leveraged to the LED upgraded cycle. Apache ( APA) downgraded to hold at TheStreet Ratings. Ball ( BLL) estimates, target reduced at Jefferies. Shares of BLL now seen reaching $42. Estimates also cut, given slower expected macro growth. Buy rating. Bio-Rad ( BIO) estimates, target cut at Jefferies. BIO estimates were reduced through 2012. Recent acquisition should hurt earnings. Company is also facing currency headwinds. Buy rating and new $135 price target. Bruker ( BRKR) rated new Outperform at William Blair. Company has a premier brand and can expand margins. Capital One ( COF) rated new Neutral at Guggenheim Securities. $42 price target. Company has higher relative risk on its balance sheet. Chevron ( CVX) downgraded at JP Morgan from Neutral to Underweight. Valuation call, based on a $101 price target. CME ( CME) estimates increased at Goldman through 2013. Company boosted its revenue guidance. Neutral rating and $290 price target. Coca-Cola ( KO) numbers cut at Goldman. Shares of KO now seen reaching $75, according to Goldman Sachs. Estimates also cut, given currency headwinds. Buy rating. Corning ( GLW) rated new Equal-weight at Morgan Stanley. Supply chain correction has not yet been fully factored into the stock. Costco ( COST) estimates, target raised at Goldman. Shares of COST now seen reaching $88. Estimates also increased, given the membership fee boost. Neutral rating. Crown ( CCK) estimates, target lowered at Jefferies. Shares of CCK now seen reaching $44. Estimates also cut, as the sector remains leveraged to slower macro growth. Buy rating. Deere ( DE) estimates, target reduced at Credit Suisse. Shares of DE now seen reaching $86. Estimates also cut, following bearish dealer checks in Europe. Outperform rating. Exxon Mobil ( XOM) downgraded at JP Morgan from Neutral to Underweight. Valuation call, based on a $90 price target. Federated Investors ( FII) upgraded at Goldman from Sell to Neutral. Stock is already pricing in interest rate risks. Forest Laboratories ( FRX) rated new Buy at ThinkEquity. $38 price target. New drugs should help re-accelerate earnings growth in the next several quarters. Liberty Interactive ( LINTA) upgraded at Citigroup from Hold to Buy. $19 price target. Stock has been excessively punished since the hard spin announcement.
Lincoln National Corp ( LNC) estimates, target lowered at Citigroup. Shares of LNC now seen reaching $18. Estimates also lowered as interest rates and equity markets remain prime risks. Manulife Financial Corp ( MFC) estimates, target lowered at Citigroup. Shares of MFC now seen reaching $10.50. Estimates also cut as balance sheet quality issues persist. Marvel Technology Group ( MRVL) estimates, target raised at Citigroup. Shares of MRVL now seen reaching $18. Estimates also increased as management reiterated expectations through September. Buy rating. Molycorp ( MCP) downgraded to sell at TheStreet Ratings. Monsanto ( MON) estimates, target boosted at Credit Suisse. Shares of MON now seen reaching $75. Estimates also upped, given higher expected growth in South America. Neutral rating. Monsanto upgraded at JP Morgan from Neutral to Overweight. $73 price target. Company should see beet seed pricing over time. Occidental Petroleum ( OXY) upgraded at JP Morgan to Overweight. $110 price target. Company is positioned to deliver above-average growth. Old Dominion ( ODFL) rated new Overweight at Morgan Stanley. $38 price target. Pricing should become more rational and the sector can rebound when the macro environment stabilizes. Pepsico ( PEP) estimates, target reduced at Goldman. Shares of PEP now seen reaching $65. Estimates also cut, given currency headwinds and slowing core growth. Neutral rating. Ralph Lauren ( RL) upgraded at Citigroup from Hold to Buy. $160 price target. Valuation call. Waddell & Reed ( WDR) downgraded at Goldman from Neutral to Sell. Asset flows could continue to deteriorate. Walgreen ( WAG) downgraded at BofA/Merrill from Buy to Neutral. $36 price target. Estimates also cut, as the ESRX loss is cutting into growth. Walgreen estimates, targets lowered at UBS. Shares of WAG now seen reaching $45. Estimates also lowered as company's margin expansion story looks more challenged near term. Buy rating.